Comparison between reduced intensity and conventional myeloablative allogeneic stem-cell transplantation in patients with hematologic malignancies aged between 50 and 59 years

Bone Marrow Transplantation

Volumn 36, Issue 8, 2005, Pages 667-674

  Kojima, R ^a   Kami, M ^a   Kanda, Y ^b   Kusumi, E ^c   Kishi, Y ^a   Tanaka, Y ^d   Yoshioka, S ^e   Morishima, S ^f   Fujisawa, S ^g   Mori, S I ^b   Kasai, M ^h,j   Hatanaka, K ⁱ   Tajima, K ^a   Mitani, K ^k   Ichinohe, T ^e   Hirai, H ^b   Taniguchi, S ^c   Sakamaki, H ^d   Harada, M ^l   Takaue, Y ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c TORANOMON HOSPITAL   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e KYOTO UNIVERSITY   (Japan)

^f Meitetsu Hospital   (Japan)

^g YOKOHAMA CITY UNIVERSITY   (Japan)

^h SAPPORO HOKUYU HOSPITAL   (Japan)

ⁱ Department of Cardiology   (Japan)

^j JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^k DOKKYO MEDICAL UNIVERSITY   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

more..

Author keywords

Allogeneic hematopoietic stem cell transplantation; Graft versus host disease; Graft versus leukemia effect; Nonrelapse mortality; Regimen related toxicity

Indexed keywords

BUSULFAN; CALCINEURIN INHIBITOR; CLADRIBINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; FLUDARABINE; METHOTREXATE; PURINE DERIVATIVE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CAUSE OF DEATH; CELLULAR IMMUNITY; CHRONIC MYELOID LEUKEMIA; CONFIDENCE INTERVAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG FATALITY; FEMALE; GRAFT SURVIVAL; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SURVIVAL TIME; WHOLE BODY RADIATION;

FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYELODYSPLASTIC SYNDROMES; RECURRENCE; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 27244454683     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/sj.bmt.1705122     Document Type: Article

References (26)

1. Biggs JC, Horowitz MM, Gale RP et al. Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy. Blood 1992; 80: 1090-1093.
2. Ratanatharathorn V, Karanes C, Lum LG et al. Allogeneic bone marrow transplantation in high-risk myeloid disorders using busulfan, cytosine arabinoside and cyclophosphamide (BAC). Bone Marrow Transplant 1992; 9: 49-55.
3. Bearman S, Appelbaum FR, Buckner C et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol 1988; 6: 1562-1568.
4. Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756-763.
5. Giralt S, Estey E, Albitar M et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: Harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531-4536.
6. Saito T, Kanda Y, Kami M et al. Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/ refractory acute leukemia/lymphoma. Clin Cancer Res 2002; 8: 1014-1020.
7. Michallet M, Bilger K, Garban F et al. Allogeneic hematopoietic stem-cell transplantation after nonmyeloablative preparative regimens: impact of pretransplantation and post-transplantation factors on outcome. J Clin Oncol 2001; 19: 3340-3349.
8. Nagler A, Slavin S, Varadi G et al. Allogeneic peripheral blood stem cell transplantation using a fludarabine-based low intensity conditioning regimen for malignant lymphoma. Bone Marrow Transplant 2000; 25: 1021-1028.
9. Diaconescu R, Flowers CR, Storer B et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood 2004; 104: 1550-1558.
10. Imataki O, Kami M, Kim SW et al. A nationwide survey of deep fungal infections and fungal prophylaxis after hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant 2004; 33: 1173-1179.
11. Bacigalupo A. Second EBMT Workshop on reduced intensity allogeneic hemopoietic stem cell transplants (RI-HSCT). Bone Marrow Transplant 2002; 29: 191-195.
12. Bacigalupo A. Third EBMT/AMGEN Workshop on reduced-intensity conditioning allogeneic haemopoietic stem cell transplants (RIC-HSCT), and panel consensus. Bone Marrow Transplant 2004; 33: 691-696.
13. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: New representations of old estimators. Stat Med 1999; 18: 695-706.
14. Yamamoto R, Kusumi E, Kami M et al. Late hemorrhagic cystitis after reduced-intensity hematopoietic stem cell transplantation (RIST). Bone Marrow Transplant 2003; 32: 1089-1095.
15. Hogan WJ, Maris M, Storer B et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78-84.
16. Fukuda T, Hackman RC, Guthrie KA et al. Risks and outcomes of idiopathic pneumonia syndrome after nonmyeloablative and conventional conditioning regimens for allogeneic hematopoietic stem cell transplantation. Blood 2003; 102: 2777-2785.
17. Fukuda T, Boeckh M, Carter RA et al. Risks and outcomes of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplants after nonmyeloablative conditioning. Blood 2003; 102: 827-833.
18. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
19. Nakai K, Mineishi S, Kami M et al. Antithymocyte globulin affects the occurrence of acute and chronic graft-versus-host disease after a reduced-intensity conditioning regimen by modulating mixed chimerism induction and immune reconstitution. Transplantation 2003; 75: 2135-2143.
20. Mielcarek M, Martin PJ, Leisenring W et al. Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. Blood 2003; 102: 756-762.
21. Fontaine P, Roy-Proulx G, Knafo L et al. Adoptive transfer of minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells without causing graft-versus-host disease. Nat Med 2001; 7: 789-794.
22. Socie G, Stone JV, Wingard JR et al. Long-term survival and late deaths after allogeneic bone marrow transplantation. Late Effects Working Committee of the International Bone Marrow Transplant Registry. N Engl J Med 1999; 341: 14-21.
23. Gomez-Nunez M, Martino R, Caballero MD et al. Elderly age and prior autologous transplantation have a deleterious effect on survival following allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning: Results from the Spanish multicenter prospective trial. Bone Marrow Transplant 2004; 33: 477-482.
24. Tallman MS, Kopecky KJ, Amos D et al. Analysis of prognostic factors for the outcome of marrow transplantation or further chemotherapy for patients with acute nonlymphocytic leukemia in first remission. J Clin Oncol 1989; 7: 326-337.
25. Hansen JA, Gooley TA, Martin PJ et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962-968.
26. Bolwell BJ. Are predictive factors clinically useful in bone marrow transplantation? Bone Marrow Transplant 2003; 32: 853-861.